The aim of this paper is to discuss biological and computational models of tumor-immune system interactions. To this end we provid first a short introduction to the field of general immunology, then a more in-depth exposition of cancer immunology. Finally we discuss a first approach to vaccine that prevent tumor onset from a biological point of view and we describe how to reproduce this phenomenon from a computational model.
Introduction
Scientific research in this new century will be mostly dedicated to the Life Sciences; all other sciences have key rules to play to support the growth of this expanding area. First of all, biologists require computer science's expertise to help store, organize and manage the enormous amount of data coming from experiments. The huge number of large data bases to date shows that this has been a successful cooperation.
However, understanding goes beyond data storage. Some insight can be achieved by statistical analysis of data but this is only a first step and it is not yet fully developed. Also required is the casting of biological phenomena in the quantitative language of maths to gain a deeper understanding and the ability to predict new scenarios to validate experimentally.
In this paper we present a success story in modeling and simulation. We studied the effect of a vaccine which prevents the onset of solid cancer. For this we modeled how the immune system response to cancer cells was triggered by the vaccine. One of the major issue in modeling tumor-immune system competition is the multiscale nature of the problem. 4 The vaccine we modeled is effective in a well-defined range of tumor evolution, i.e. from atypical hyperplasia to multiple metastatic tumors. For this reason, our model refers only to cellular scale. This work is now included in a large European project entitled IMMUNOGRID a whose aim is to simulate the human immune system. The plan of the paper is the following. In Sec. 2 we present a short primer of immunology principles. Section 3 will introduce basic concepts of tumor immunology while Sec. 4 focuses on tumor immunoprevention. In Secs. 5 and 6 we describe how to reproduce the immune system-cancer-vaccine competition within a computational model. Section 7 shows how to use the model for designing vaccination schedules. Finally in Sec. 8 we present our conclusions and perspectives.
Basic Principles of Immunology: A Short Primer

The concept of immunity
All multicellular organisms have evolved defense mechanisms against the onslaught of viruses, bacteria, and other parasites. The immune system of vertebrates combines evolutionarily innate (or natural) immunity with newer adaptive responses against specific antigens. It is important to keep in mind that the two systems are tightly integrated, and several molecules and cells, in addition to their fundamental role in one system, act as interfaces between the two. In the first part of this review we will briefly examine the main elements of innate and adaptive immune responses. An excellent reference for further reading is the textbook by Abbas and Lichtman. 
The elements of innate immunity: Physical barriers, soluble mediators, cells and their receptors
The main elements of innate immunity are physical barriers, soluble mediators that directly inhibit foreign micro-organisms and specialized cells endowed with recognition receptors and with the ability to phagocytose and kill microorganisms.
Physical barriers are sometimes underestimated as part of the immune system, even though it is common wisdom that an intact skin is a very effective protection from infection, while even superficial wounds can be easily colonized by foreign invaders. In addition to skin, physical barriers include the blood coagulation system that stops bleeding and forms a protective clot over wounds, and internal mucosae, protected by mucus and continuously cleansed by the action of ciliated cells that sweep away bacteria and other materials. The mildly acidic pH of skin inhibits bacterial proliferation, and the very acidic pH of stomach juices effectively sterilizes ingested material.
A variety of soluble molecules present on the skin, in secretions, in blood, and throughout the body directly kill bacteria and inhibit viral infections. Prominent examples are defensins (natural antibiotics), the lysozyme (an enzyme that lyses the wall of some bacteria), complement (a cascade of proteins activated by bacterial components that make holes in bacterial membranes), opsonins (complement fragments and other proteins that coat bacteria and facilitate phagocytosis) and some ancient cytokines such as type I (α and β) interferons that are released by virus infected cells and induce an anti-viral state in neighboring cells.
Cellular migration toward invaders and phagocytosis are the basic cellular mechanisms of innate immunity, followed by intracellular destruction of the ingested micro-organism. Extracellular killing is also possible if phagocytes release lytic substances in the environment. In mammals the two main cell types are granulocytes, which contain lytic substances packed in intracellular granules (also called polymorphonuclear cells because their nucleus is of irregular shape) and macrophages. Neutrophil granulocytes have an important role in defense against bacterial infections, basophils have an anti-parasitic role. Macrophages derive from circulating monocytes that emigrate to practically all tissues and organs, sometimes under different names (e.g. Kupffer cells in the liver). In addition to immune functions, macrophages play important roles in the turnover of aging cell components, like red blood cells which are continuously phagocytosed by splenic macrophages. Natural killer (NK) cells are non-phagocytic elements that kill virus-infected cells; it is worth noting that the evolution of NK cells is relatively recent and goes in parallel with the evolution of lymphocytes, to which NK cells closely resemble from a morphological point of view.
Recognition in innate immunity is mediated by interactions with pathogenassociated molecular patterns expressed by micro-organisms. Cellular receptors are globally referred to as "pattern-recognition receptors" and include the family of Toll-like receptors (TLR), mannose receptors (MR) and seven-transmembrane spanning receptors (TM7). TLR recognize bacterial and viral nucleic acids, flagellin, bacterial peptides, lipopolysaccharide (LPS) and other bacterial components. MR bind carbohydrate moieties on several pathogens, such as bacteria, fungi, parasites, and viruses. TM7 receptors are activated by bacterial peptides or by endogenous chemokines.
The hallmarks of adaptive immunity: Specificity, memory, tolerance
The evolution of adaptive immunity accompanies the evolution of vertebrates, starting from sharks. It is therefore conceivable that part of the evolutionary success and long life spans of vertebrates could be attributed to the improved defenses against exogenous pathogens. The functions of adaptive immunity are performed by a new type of cell (the lymphocyte) which recirculates between blood, tissues and a specialized circulatory system (the lymphatic vessels) and reside in specialized organs (lymphoid organs, which include the thymus, the spleen and lymph nodes).
The hallmarks of adaptive immune responses are specificity, immune memory and immune tolerance. The immunological meaning of specificity refers to the fact that a lymphocyte population is composed of millions of clones, each specific for a different antigen. Specificity is encoded in clonotypic antigen receptors generated by a process of DNA rearrangement that includes random events to produce billions of variant molecules from a relatively small pool of DNA sequences.
Specificity allows a considerable economy in adaptive immune responses to pathogens, because only the clones expressing receptors for a specific microorganism are activated upon infection, while all other clones remain inactive. In addition to the proliferation of specific lymphocyte clones, the first encounter with a given antigen (primary immune response) leaves behind a population of memory cells that will respond more promptly and more efficiently to subsequent encounters (secondary immune response). The presence of random events in the generation of specific antigen receptors implies the risk of producing autoreactive receptors. To prevent autoimmunity, the differentiation of lymphocytes is accompanied by selective mechanisms that ensure tolerance to autologous (self) components through the destruction or the inactivation of autoreactive clones.
Repertoire and receptor rearrangement
How many different antigens can be specifically recognized by the adaptive immune response? A theoretical estimate is of the order of 10 20 . Given that mammalian genomes contain between 10 4 and 10 5 different genes, one might wonder how to encode such a large repertoire of specific antigen receptors. The answer resides in a unique DNA rearrangement that happens only in lymphocytes to produce antigen receptor genes. Antigen receptor genes comprise two or three sets of 10 1 -10 2 alternative segments encoding the variable, antigen-binding part (V , D and J segments) separated by non-coding DNA segments and followed by one or a few segments encoding the constant (C) part of the receptor. During lymphocyte differentiation one segment from each variable set is chosen at random and brought in proximity to one another by enzymes that cut and discard the intervening DNA. At the end of the process the rearranged DNA of lymphocytes is different from that of all other cells of the organism, originally inherited by the individual (the so-called germline configuration), and each lymphocyte contains a slightly different sequence encoding the antigen receptor. Receptor diversity is further increased by enzymes that cause sequence alterations at the point of contact between the various segments (junctional diversity) and by the fact that functional membrane antigen receptors are dimers of molecules encoded by separate genes, each undergoing DNA rearrangement independently.
Cells and molecules of adaptive immunity
Lymphocytes comprise populations with different types of antigen receptors and diverse functions. The most fundamental distinction is between T and B cells. B cells use immunoglobulins (Ig) as membrane antigen receptors and, after receptor stimulation by the antigen, differentiate into plasma cells which actively secrete a soluble form of the receptor, called antibody. Each molecule is a dimer of a heavy and a light chain, each with a variable and a constant part. The basic antibody molecule is Y -shaped and has two independent antigen-binding sites (at the ends of the diagonal segments of the Y ). The stem of the Y is constant and mediates the so-called effector functions of the antibody. Most mammals have multiple C segments in their genome, giving rise to different classes of antibodies. IgM are the first antibodies produced in primary immune response, IgM molecules are assembled from five basic molecules, thus have ten antigen-binding sites. IgG are the main class of antibodies produced in secondary immune responses and released in the bloodstream. In humans there are four different IgG types (IgG1, IgG2, IgG3 and IgG4) endowed with subtle differences in their functions. IgA are specialized for functioning in secretions like milk, tears, saliva and intestinal juices rather than in blood. IgE are best known in connection with allergies (see below). The function of antibodies is to bind to and inactivate their cognate antigens. This is accomplished through various mechanisms. Binding of multiple antibody molecules to multiple antigens can yield an insoluble antigen-antibody complex that is rapidly removed from the blood. Antibody binding to cell membranes activates complement components that can lyse the bound cell. Various leukocytes express surface receptors for the constant part of antibodies that mediate further functions such as phagocytosis (opsonization) and cell lysis (antibody-dependent cell-mediated cytotoxicity, ADCC). In this way cells of the innate immunity, such as the macrophages or NK cells acquire the antigen specificity of adaptive immunity. Other antibody receptors mediate the passage of maternal antibodies through the placenta and the intestinal uptake of antibodies present in maternal milk, thus conferring a passive protection to the fetus and to the lactating newborn.
T cells use a different type of surface antigen receptor (TCR). A major conceptual difference between T and B responses is that antibodies are at the same time the receptor and the effector molecule of B cell immunity, while the TCR is a membrane receptor that activates a signaling cascade culminating in effector actions mediated by other molecules. A second important difference is that antibodies bind practically any conceivable molecular species, from proteins to sugars and lipids, to small organic molecules, whereas the TCR recognizes small peptides derived from cellular metabolism of proteins. A third difference is that the antigen-binding site of antibodies recognizes the antigen in its free native form, whereas the TCR only recognizes peptides present on the cell membrane bound to a cellular protein called the major histocompatibility complex (MHC).
T cells comprise various subpopulations with different functions. Cytotoxic T cells (Tc, also referred to as CTL) directly kill cells expressing the antigen, helper T cells (Th) positively regulate the activity of B and Tc cells, while regulatory T cells (Treg) inhibit immune responses. The activity of Th and Treg is mediated both by direct cell-cell contact and by cytokine secretion. Th cells are further divided into type 1 and type 2 cells (Th1 and Th2) according to the spectrum of secreted cytokines and the type of immune response they help: Th1 cells release γ-interferon (IFN-γ) and other cytokines to stimulate immune responses directed against viruses and intracellular bacteria, whereas Th2 cells release interleukin 4 (IL-4) to stimulate the immune response against parasites. There are various molecular markers that distinguish T cell subpopulations, among them CD8 for Tc and CD4 for Th. CD4 is also well known for being used by the human immunodeficiency virus (HIV) to infect helper T cells.
The adaptive immune response
The adaptive immune response involves a complex interplay of different cells. As an example we will follow from beginning to end an anti-viral response to explain the various cellular and molecular interactions. The immune response begins when viral proteins are captured in the periphery of the body (e.g. skin, mucosae, etc.) by a specialized population of leukocytes called dendritic cells (DC). DC migrate to lymph nodes where they present to Th cells antigenic peptides generated from viral proteins and exposed on the DC membrane in association with MHC molecules. 
Immune tolerance
Random generation of antigen receptors entails the risk of generating self-reactive immune responses (autoimmunity). Various differentiative and evolutionary biologically natural processes are intrinsically irreversible, and the natural way to cope with useless or potentially harmful cells is to produce the cells first and to destroy them afterwards.
T cells produced by hemopoiesis in the bone marrow migrate to the thymus where T cell rearrangement takes place followed by counterselection of clones expressing inappropriate receptors (clonal deletion). As soon as newly differentiated T cells express the rearranged TCR they interact with autologous MHCpeptide complexes expressed by thymic cells. Autoreactive T cells that recognize autologous MHC-peptide complexes die by apoptosis (negative selection), as do T cells with missing or defective TCR that completely fail to interact with autologous MHC. Only T cells whose TCR interacts with appropriate affinity with the MHC, thus potentially reactive with foreign antigens, survive and thrive (positive selection). It is said that T cells are educated in the thymus, but we must keep in mind that the thymus is a harsh mistress: more than 90% of T cells are killed during the selection process. It is interesting to note that thymic cells express a wide range of peptides, including those of proteins usually produced by specialized tissues and organs, like the pancreas and the thyroid, hence T cells in the thymus are exposed to a comprehensive sampling of the peptides they will subsequently encounter in the periphery.
Deletion of autoreactive clones in the thymus (central tolerance) is not 100% efficient, therefore all normal adults harbor autoreactive T cells that are rendered harmless by tolerogenic processes in the periphery of the body. Peripheral tolerance is the result of the dependence of T cell activation from antigen presentation by APC. Only APC express appropriate costimulatory molecules required (in addition to the MHC-peptide complex) to activate T cells. If a T cell encounters the antigen on a parenchymal cell lacking costimulatory molecules the ability of the T cell to be activated is inhibited (anergy).
Immunopathology: Autoimmunity, allergy, immunodeficiency, transplantation immunity
We have so far dealt with physiological immunity. We will conclude this primer on immunology with a brief mention of the main pathological processes. Autoimmune diseases are caused by a break down of tolerance. Anergic autoreactive cells can be activated by infection, either because the foreign micro-organism expresses antigens similar to autologous molecules (antigen mimicry), or because it causes a copious release of cytokines (a "cytokine storm") that non-specifically activate numerous clones, including the autoreactive ones. The events triggering autoimmune responses are better investigated in experimental models than in human patients, because the preclinical immune events of most human autoimmune diseases are obfuscated by the progressive expansion of the immune response that extends to multiple antigenic determinants (determinant spreading).
Allergy is a pathological immune response (hypersensitivity) to specific antigens (allergens) contained in food, dust, pollens, animal components, chemical products and drugs. Recognition of the allergen elicits a Th2 response leading to IgE antibody production and capture by receptors on the surface of mast cells and basophil granulocytes (sensitization phase). Allergen binding then triggers the release from cells of various mediators, such as histamine, prostaglandins and cytokines, which cause the allergic reaction. The type of reaction is typically related to the mode of entry of allergens, e.g. inhaled pollens cause hay fever with sneezing and cough, while food allergens cause gastrointestinal reactions. The most severe type of allergic reaction, anaphylactic shock, may result from allergen injection, for example bee stings.
A lack of immune response is caused either by heritable genetic defects (primary immunodeficiency) or by extrinsic causes such as HIV infection or drug treatments (secondary immunodeficiencies). The fact that all immunodeficient individuals experience a significant increase in sensitivity to chronic and lethal infections is a clear illustration of the defensive role of the immune system toward microorganisms.
The advent of organ transplants fostered the birth of many new concepts in immunology. Transplantation of cells, organs or tissues between unrelated individuals elicits in the recipient a very strong immune response that rapidly destroys the graft. The cause of tissue incompatibilities within a given species is the expression of different antigens (alloantigens) between individuals. Rejection in humans is caused either by recipient antibodies binding AB0 blood antigens expressed by the blood vessels of the transplanted organ or by T cells recognizing donor MHC antigens expressed by all cells of the organ. Historically, MHC antigens were discovered and named for their role in allograft rejection. The clinical solution to the problem of organ rejection came from the discovery of immunosuppressive drugs like cyclosporin that block T cell activation and response.
Tumor Immunology
To analyze the immune response against tumors we will address two fundamental questions: (a) how and when does the immune system defend us from tumors, and (b) what can be done to improve immune responses against tumors.
Immunodeficiency and cancer
The clearest illustration of the antitumor importance of the immune system comes from the study of genetically-modified models (GEM) of mice designed to lack immune responses. Such immunodepressed mice develop multiple malignant tumors at an age when congenic immunocompetent mice are mostly tumor-free, and are also more prone than normal mice to chemical carcinogenesis. 25, 9 It must be noted that the advent of GEM has profoundly revolutionized tumor immunology and all biomedical sciences. "Designer" modifications to the genome allow a precise dissection of the role of genes, cells, and functions in biology and in pathology. Tumor immunology is a case in point: the results of definitive experiments with GEM mice performed after year 2000 were hypothesized five decades earlier by the theory of immune surveillance of tumors, but earlier studies with spontaneous mouse mutants, such as nude mice, yielded contradictory results because the immunodepression of such models is not stable in time and tends to decrease with age, exactly when tumor incidence increases. The complexity of the situation in mouse models is reflected by humans. Severe primary immunodeficiencies are either lethal at an early age or are cured by various medical treatments, therefore there are no aging humans with a persisting complete immunodeficiency. Two groups of immunodepressed human adults are transplantation recipients receiving immunosuppressive drugs and acquired immunodeficiency syndrome (AIDS) patients. In both cases the level of immunodepression is quite variable, and the presence of concomitant pathologies and drug treatments complicate the study of tumor incidence. Nonetheless the emerging picture is quite clear: the incidence of various tumor types is significantly increased in immunodeficient individuals. This includes lymphomas and leukemias, melanoma, and all virus-related tumors such as Kaposi's sarcoma or carcinoma of the uterine cervix. To summarize, animal models and human studies clearly demonstrate that a physiological role of the immune system is to prevent tumor growth.
Immunoediting
The fact that tumor incidence in mouse and humans is nonzero obviously demonstrates that immune surveillance of tumors is not 100% efficient. The original theory of immune surveillance predicted that tumors reaching macroscopic dimensions must have escaped immune defenses. A contemporary comparison of tumors arising in immunocompetent versus immunodepressed mice showed that the former are much less immunogenic than the latter, because the presence of immune responses counterselects immunogenic tumor variants, eventually leading to the emergence of poorly immunogenic macroscopic tumors. This process was named "immunoediting" of tumor antigenicity. It is generally assumed that most spontaneous tumors, arising with very long latency times, are indeed poorly immunogenic. This includes the majority of human tumors.
Immune cells with antitumor activity
The analysis of immune responses in normal and GEM mice revealed that the various cells and molecules of immunity have different roles and relative importance in tumor immunity.
Starting with innate immunity, macrophages and other phagocytes are important because they can directly destroy tumor cells and also because they can produce tumor cell fragments that can be picked up by antigen presenting cells. Presentation of tumor antigens is mainly effected by dendritic cells (DC), a crucial component of the immune response which is currently the focus of various immunotherapeutic attempts. NK cells kill tumor cells with a low MHC expression; they are the sole leukocyte type active in the bloodstream, hence they have an important role in the defense against circulating metastatic cells.
In the context of adaptive immunity, current tumor immunology is dominated by T cells, while B cells and antibodies are generally thought to be irrelevant, because solid tumors generally express inhibitors of complement and are mostly resistant to lysis by antibodies and complement. In some instances it has even been demonstrated that B cells can favor tumor growth, possibly through their tolerogenic antigen presentation. It must be said that the T cell chauvinism of many tumor immunologists is not fully justified. We shall see that the first and only clinically approved "drugs" deriving from tumor immunology are indeed antibodies, and that the B cell response to cancer vaccines can play an important role.
Both Th and Tc (CTL) cells are very important in antitumor responses, the former because they help all other immune responses, the latter because they directly destroy tumor cells. Treg cells can suppress antitumor immune responses and many studies are currently aiming at inhibiting Treg activity to enhance tumor immunity.
Tumor antigens
Tumor antigens recognized by the immune system comprise a wide set of molecules, discovered over the past five decades using diverse search strategies and technological tools. Here we will deal only with those antigens that are recognized by the immune system of the host. This is a trivial, but important, distinction that leaves out, for example, human molecules that are detected with mouse immunological reagents, but are actually ignored by the human immune system. Such molecules are sometimes referred to in the literature as "tumor antigens", but we think that "tumor markers" would be a more appropriate term.
The main classes of tumor antigens and a few examples in each class are shown in Table 1 , for a complete listing the reader is referred to the database compiled by Giorgio Parmiani and co-workers. 20 An important point outlined in the table is that many antigens are expressed by normal cells in addition to tumor cells. This implies that immune responses against such antigens are actually autoimmune responses. This fact contributes to explaining why the immunogenicity of tumor antigens is scarce: as "self" molecules they are subject to immune tolerance, and tolerance must be broken to elicit powerful immune responses. Cancer/testis antigens were the first antigens to be cloned using syngenic T cell-based technologies in the early '80s. The immunological value of molecules previously discovered using xenogenic antibodies (e.g. through the immunization of mice with human tumor cells) is dubious. The use of "search strategies" based on syngenic T cells guarantees immune recognition in the host of origin, and potential "Shared" tumor antigens are found in tumors of different histotypes, and are also expressed by various normal tissues. A quantitative discrimination between normal and tumor cells is made possible by the fact that tumor cells frequently express huge amounts of the antigen.
The only true tumor-specific tumor antigens result from point mutations or chromosomal translocations in oncogenes or tumor suppressor genes that cause cancer. The existence of T cell clones specific for mutant oncoproteins has been demonstrated, however the ensuing immune responses are not particularly strong, and up to now the few clinical attempts at making vaccines against tumor-specific antigens have proved ineffective and exceedingly cumbersome (because of the rarity of each individual mutation in a given set of patients). Another type of unique tumor are the idiotypes of T and B cells. Idiotypes are antigenic determinants normally present in the antigen-binding site of TCR and Ig. If a neoplastic T or B cell clone maintains expression of its antigen receptor, then it also expresses an idiotypic determinant that can be targeted by specific immune responses. Among tumor-specific tumor antigens only idiotypes, in particular B cell idiotypes, have so far shown some clinical perspective as targets of immunotherapeutic endeavors.
Defense and counterattack of tumor cells
Studies of the competition between the tumor and the immune system revealed multiple strategies set forth by tumor cells to avoid immune attack, or even to counterattack and defuse immune defenses.
Tumor antigens are not expressed by all tumors, and within tumors there is frequently a considerable heterogeneity of antigen levels between cells, frequently leading to a decrease of antigenicity in later stages of tumor progression. Metastases frequently show a lower antigenicity than primitive tumors.
Recognition and lysis of tumor cells by Tc cells depends on the expression of an MHC-peptide complex on the surface of tumor cells. Loss of MHC expression is extremely frequent in tumors. Detailed studies showed that more than 85% of all human tumors have a decreased MHC expression when compared with normal cells. Down-regulation of MHC appears to be the most common way to evade the immune response. As a complete loss of MHC expression would lead to recognition by NK cells, the MHC level of tumors appears to be adjusted to simultaneously minimize T and NK recognition.
In general tumor cells lack costimulatory molecules required for antigen presentation to T cells. Recognition of an antigen in the absence of costimulatory molecules can anergize T cells, hence in the absence of appropriate antigen presentation tumor cells promote tolerance.
In addition to the evasion mechanisms described above, tumor cells can actively inhibit immune responses. One mechanism is the release of inhibitory cytokines, such as transforming growth factor β (TGF-β), which in some case can, at the same time, promote tumor growth, and interleukin 10. TGF-β and other tumor-derived cytokines activate Treg and other suppressive cells of myeloid origin that inhibit T cell responses. Finally tumor cells can express surface receptors that directly induce death by apoptosis of immune cells upon cell-cell contact.
Cancer immunotherapy: Clinical impact of tumor immunology
The investigation of tumor immunity has led to many clinical attempts at curing human tumors (immunotherapy). Once a therapeutic agent has demonstrated its efficacy, it can be approved for routine use by regulatory agencies such as the Food and Drug Administration (FDA) in the US or the Agency for the Evaluation of Medicinal Products (EMEA) in Europe. The type of approved molecules can also be used as an index of the efficacy of various therapeutic approaches. In the context of immunotherapy of tumors the only approved molecules are monoclonal antibodies directed against tumor antigens, such as HER-2, or against antigens expressed by the tumor stroma. The number of approved monoclonal antibodies is increasing, and many more are in development, thus illustrating the effectiveness and the success of this immunotherapeutic approach.
Reasons for the clinical efficacy of monoclonal antibodies are manifold. First, some monoclonal antibodies are directed against tumor cells that are sensitive to complement-mediated lysis, for example lymphomas. Second, the antigens targeted by monoclonal antibodies on solid tumors are growth factor receptors directly involved in the proliferation of tumor cells. In this case antibody binding disrupts signaling circuits and directly inhibits tumor growth in addition to the cytotoxic events mediated by complement or by ADCC.
Various cytokines were tested as therapeutic agents against cancer, but in many instances produced toxic effects that forbade a clinical use. It must be kept in mind that most cytokines physiologically act at locally high doses, but systemic concentrations are usually negligible. One case which allows systemic administration at high doses is α-interferon (IFN-α), which is active against leukemias and is used also for some solid tumors, mainly melanoma. IFN-α activity is based on direct inhibition of tumor cell growth, induction of tumor cell differentiation, and stimulation of immune responses.
Many therapeutic vaccines have been tested over the years to stimulate antitumor T cell responses in cancer patients. In general results are discouraging, with sizeable tumor regressions in a small percentage of patients. As a result, vaccines remain in the experimental territory, none has been approved for routine use.
One last approach is "adoptive" immunotherapy, based on the transfer of cells, obtained either from donors or from patients themselves. A successful therapy is the transfer of allogenic (donor) T lymphocytes in leukemia patients ("graft-versusleukemia"), accompanied however by a considerable risk of toxicity. Attempts based on ex vivo stimulation with IL-2 of patient T and NK cells have met with little success and were largely abandoned. A type of adoptive immunotherapy currently under extensive clinical evaluation is based on the in vitro culture of DC from patients, followed by in vivo reinfusion of DC preloaded with tumor antigens, in the hope that DC will present tumor antigens and trigger T cell responses against tumor cells.
Immunoprevention of Tumors
From cancer immunotherapy to cancer immunoprevention
We have seen in the previous section that the clinical impact of cancer immunotherapy is mottled, in particular cancer vaccines were mostly ineffective as therapeutic agents. An evaluation of the preclinical results of vaccines in mouse models shows a clear dichotomy between therapeutic and prophylactic uses of vaccine. The classical experiment is the "immunization-challenge" system, in which a mouse separately receives a vaccine and an injection of replicating tumor cells (the challenge). In most instances vaccination before the challenge (prophylactic vaccination) prevents tumor growth, whereas vaccination after the challenge (therapeutic vaccination) is much less effective. This is a generalized finding that led some tumor immunologists, including the authors, to ask whether it was indeed possible to implement a new type of cancer prevention based on cancer vaccines (immunoprevention).
Cancer prevention
Tumors are caused by a combination of exogenous and endogenous factors. Elimination of exogenous factors is in principle quite easy. Industrial carcinogens are banished from the working environment by governmental decrees and laws. Recreational carcinogens, like tobacco smoke, are progressively abandoned as a result of educational campaigns and changes in lifestyle. For some types of cancer the elimination of exogenous factors would lead to almost complete disappearance of the cancer itself. For example more than 90% of lung cancers are attributed to tobacco smoke, therefore in a smokeless world the incidence of lung cancer would be reduced by 90%. Other tumors are mainly due to endogenous or unknown factors, for example the major risk factors for breast cancer are related to hormonal (estrogenic) stimulation of the mammary gland during fertile life. One possible way to prevent such tumors is the administration of chemical compounds that inhibit the endogenous biochemical pathways linked to carcinogenesis (chemoprevention). For example, large clinical studies in thousands of women demonstrated that the chronic administration of selective estrogen receptor modulators like tamoxifen reduce the risk of breast cancer by half. However tamoxifen, as all drugs, is not devoid of harmful side effects, which include an increased risk of deep venous thrombosis, cerebral vascular accidents and endometrial cancer. In summary, chemoprevention is not perfect, and further preventive strategies, like immunoprevention, would be welcome in cancer prevention.
The HER-2/neu transgenic mouse model
As mentioned above it is possible to vaccinate mice against a subsequent challenge with cultured tumor cells, but the abrupt injection of thousands or millions of malignant cells is a situation quite different from the lengthy spontaneous onset of tumors, accompanied by a stepwise progression from premalignant lesions, to carcinoma in situ, to invasive carcinoma.
To investigate cancer immunoprevention we opted for transgenic mouse model systems that recapitulate the entire natural history of tumors. Mice transgenic for the HER-2/neu oncogene (involved also in human breast cancer) are prone to mammary carcinomas that spontaneously develop over the course of several months. This is a very flexible system that was independently produced by various laboratories using mice differing in their genetic background and different transgenes of human or rat origin, either in normal (prototoncogenic) form or harboring activating mutations. Here we will deal with a transgenic line named BALB-neuT that harbors a mutant rat HER-2/neu expressed in the mammary gland under transcriptional control of a mouse mammary tumor virus sequence.
Soon after birth in the mammary glands of BALB-neuT mice appear cells hyperexpressing HER-2/neu gene product, p185. Such cells start proliferating and give rise to multiple microscopic lesions identifiable as atypical hyperplasia (a preneoplastic condition), then progress to multiple carcinomas in situ, the first frank neoplastic lesion. Carcinomas in situ continue growing and coalesce into carcinomas that become macroscopically apparent around 4-5 months of age. Tumor formation proceeds independently in all ten mammary glands and, in later stages, gives rise to metastases detectable in the lungs.
Mammary carcinoma immunoprevention in HER-2/neu transgenic mice
Starting in the mid-'90s various attempts were made by us and others to prevent mammary carcinoma in HER-2/neu transgenic mice using immunological maneuvers. It was shown that it is indeed possible to inhibit carcinogenesis using different immunological approaches that included the administration of monoclonal antip185 antibodies and treatments aimed at actively eliciting host responses, either in a non-specific way (e.g. with IL-12) or with anti-HER-2/neu specific vaccines consisting of whole cells, proteins, peptides or DNA. The convergence of many independent approaches indicates that immunoprevention is indeed a viable concept. However, a quantitative analysis of the first published studies, including our own, shows that immunological treatments only delayed carcinogenesis, and in most instances all mice succumbed to tumors with a latency time only slightly (albeit significantly) longer than tumors of untreated mice.
The Triplex vaccine
To improve the efficacy of existing immunopreventive treatments we adopted a standard approach in oncology, i.e. we combined multiple immune signals in the same vaccine. The Triplex vaccine combines the target antigen with two "adjuvant" stimuli, IL-12 and allogeneic MHC molecules. The main purpose of IL-12 is to enhance antigen presentation and Th cell activation in response to the antigen. Allogeneic MHC molecules stimulate multiple T cell clones and cause a broad production of immunostimulatory cytokines that amplify immune responses. The first formulation of the Triplex vaccine consisted of MHC-allogeneic mammary carcinoma cells expressing HER-2/neu and of recombinant IL-12. Subsequently the need for IL-12 administration was bypassed through the transduction of vaccine cells with IL-12 genes (see below).
Block of mammary carcinoma development in vaccinated mice
Repeated administrations of the Triplex vaccine to young BALB-NeuT mice resulted in a complete block of mammary carcinogenesis. More than 85-90% of vaccinated mice remained tumor-free at one year of age, whereas all untreated mice had multiple mammary carcinomas at six months of age. In practice the Triplex vaccine more than doubled the life expectancy of BALB-NeuT mice. In a few groups of mice we continued the vaccination beyond one year, and we found that the vaccine had restored a life expectancy of between two and three years, similar to that of non-transgenic mice. Detailed molecular and microscopic studies revealed that vaccinations had effectively "frozen" mammary carcinogenesis at the level of atypical hyperplasia, without any detectable development of carcinomas. Interestingly, the mammary glands of vaccinated mice of all ages showed little or no expression of HER-2/neu. It is generally assumed that cells expressing HER-2/neu are continuously generated in the mammary glands of transgenic mice, hence the absence of HER-2 expression in vaccinated mice indicates that immune responses either continuously eliminated cells expressing the oncogene, or actively downmodulated its expression.
Protective immune mechanisms elicited by the Triplex vaccine: Th and antibodies
The analysis of immune responses elicited by the Triplex vaccine yielded some surprises. We did not find evidence of cytotoxic T cell responses, instead vaccinated mice showed strong anti-HER-2/neu antibody titers and a copious production of Th cytokines, in particular γ-interferon (IFN-γ). To formally define the protective role of the various responses we obtained (through crossing with knockout mice) BALBNeuT lacking either IFN-γ or antibody production. The Triplex vaccine failed to protect such immunodepressed mice, demonstrating that IFN-γ and antibodies were responsible for cancer prevention. It is interesting to note that BALB-NeuT mice lacking IFN-γ produced some immunoglobulin subclasses (IgG1), but not others (IgG2a), whereas antibody-deficient mice produced IFN-γ. Experimental results led us to the following conceptual model: the Triplex vaccine induces activation of Th cells secreting IFN-γ, which has a major role in inducing the isotype switch of anti-HER-2/neu B cells to IgG2a. Other actions of IFN-γ (e.g. inhibition of tumor cell proliferation, induction of antiangogenic molecules) are also present, but play a minor role. The final immune effectors of cancer prevention are antibodies against HER-2/neu of the IgG2a (and possibly other) subclass, which have multiple antitumor activities mediated by immune mechanisms (complement-mediated cytotoxicity, ADCC) and by direct inhibition of HER-2/neu oncogenic signaling (induction of membrane p185 recycling and inhibition of dimerization). The combination of different mechanisms causes the disappearance of cells expressing HER-2/neu from the mammary glands through direct killing, downmodulation of p185 expression and apoptosis caused from the lack of mitogenic signals.
New target antigens for cancer immunoprevention and immunotherapy
The analysis of results and mechanisms of immunoprevention suggest some new immunological concepts that might be useful for the clinical development of immunoprevention itself and also to modify some paradigms of cancer immunotherapy. One reason why immunoprevention was successful in HER-2/neu transgenic mice is because HER-2/neu in these mice is at the same time the oncogene driving mammary carcinogenesis and the target antigen. Many tumor antigens are not indispensable for tumor growth, but experimental data have shown that in transgenic cells the loss or down-modulation of HER-2/neu expression blocks the ability to form tumors. This rules out the generation of tumorigenic antigen-loss variants, because the loss of the antigen would at the same time cause the loss of tumorigenicity.
A second important property of HER-2/neu is its accessibility to antibodies because of its membrane localization. Many internal tumor antigens recognized by T cells as processed peptides depend from the presence of MHC molecules, however we have seen that most tumors downmodulate MHC and become resistant to T cell immunity. Antibodies against HER-2/neu are equally effective against MHC-positive and MHC-negative tumor cells.
If we look at the current database of tumor antigens we find very few molecules with the properties of HER-2/neu. Most tumor antigens are not expressed on the cell surface, thus antibodies directed against them cannot inhibit tumor cells. Many surface molecules are not involved in carcinogenesis, and can be downmodulated by tumor cells without consequences for their tumorigenicity. We think that further research should be directed at pinpointing new tumor antigens that share with HER-2/neu the properties of being surface molecules required for carcinogenesis. The number of potential candidates is huge and includes many growth factor receptors and various other classes of surface molecules.
12 Such new types of tumor antigen will be indispensable for cancer immunoprevention, furthermore they could be important also as new targets for cancer immunotherapy.
Immunoprevention of diverse tumors
HER-2/neu transgenic mice are the most thoroughly investigated model of cancer immunoprevention, however many other types of tumors were prevented using analogous approaches. Immunoprevention has been demonstrated for carcinogen-induced sarcomas in non-transgenic mice and spontaneous tumors in different transgenic mouse models, including colorectal tumors, prostate cancer, cutaneous carcinomas, and sarcomas. These results suggest that immunoprevention could be applied in principle to any tumor type.
The challenges of translating preclinical results to human health
The results illustrated above indicate that cancer immunoprevention is in a mature phase of preclinical development and is ready for human application. However, it is highly unlikely that such a new preventive approach might be directly applied to healthy humans, in particular because the potential harmful side effects of immunoprevention are largely unknown. Induction of autoimmunity is a theoretical risk that was not excluded by animal studies. It is likely that early applications to humans will be in a therapeutical setting in advanced cancer patients, to better evaluate toxicity ("phase I" clinical studies).
Unsolved issues in transgenic mouse models of cancer immunoprevention
When a newly designed vaccine is ready to be administered for the first time in vivo, either to mice or to humans, the schedule is designed empirically, using a combination of immunological knowledge, vaccine wisdom experience from previous endeavors, and practical constraints. In subsequent trials the schedule of vaccinations is then refined on the basis of the protection elicited in the first batch of subjects and of their immunological responses (e.g. kinetics of antibody titers, cell mediated response, etc.).
For the sake of illustration we will briefly revisit here the history and the choices that led to the development of the Chronic schedule of the Triplex vaccine. The roots of this prophylactic protocol are in therapeutic experiments performed in the second half of the '90s. Our group in Bologna was studying MHC allogenic gene-transduced therapeutic cell vaccines 11 and had perfected a schedule based on two intraperitoneal vaccinations per week 23 , while Forni and Cavallo in Turin were using recombinant IL-12 (as a control) with a schedule based on courses of five daily injections of the cytokine. 7 The first attempts at cancer prevention in HER-2/neu transgenic mice were conducted with one course of IL-12 per month for the entire lifetime of the mouse. 6 To improve on those early results we then decided to combine IL-12 and an allogeneic cell vaccine, using a robust number of cell administrations (two intraperitoneal vaccinations per week for two consecutive weeks) followed by one week of IL-12. We then decided to give one week of rest to the mice (and investigators) and to repeat the four-week cycle until the mice showed some sign of tumor development. As this protocol completely prevented tumor development in most mice, we arbitrarily decided to stop the experiments when the mice were one year old, a time span sufficiently long to allow a statistically significant and very convincing separation of survival curves from those of untreated mice. 19 The latest refinement was the transduction of vaccine cells with IL-12 genes, which eliminated the need for systemic IL-12 administration (a potential source of toxicity in humans) and reduced the schedule to just two weeks of cell vaccinations followed by two weeks of rest, to be repeated for one year. 8 This last schedule, referred to as the Chronic schedule, was implemented in silico as described below. The major issue still unresolved with the Triplex vaccine is whether or not the Chronic schedule is the minimal set of vaccinations yielding complete, longterm protection from mammary carcinoma. Shorter vaccination protocols failed to prevent cancer, but between shorter protocols and the Chronic one there still is an infinite set of schedules that might yield complete protection with significantly fewer vaccinations. From an experimental point of view this would require numerous sets of experiments each lasting one year, a feat that discouraged the biological part of our team from the pursuit of an experimental solution in vivo.
Before we move into the description of the in silico simulator we used, we must stress that the matter at stake is not a problem of biological laziness, but rather of translational research. We are not in this business just to prevent mouse tumors, our final goal is to devise strategies that could be implemented in humans. The Chronic protocol would lead to human protocols entailing frequent vaccinations for the entire lifetime of subjects at risk of cancer, making for a very cumbersome and unpractical attempt at translating promising preclinical results. We think that biological experiments based on the results of the simulations described here could ease clinical translation.
Modeling and Simulations
To design a simulated schedule, one should take into account not only general knowledge of the immune system but also what is specifically known from the experiments for that specific vaccine. This means that we are involved in designing a general model of the immune system-tumor-vaccine interaction including, in detail, what is known about the specific vaccine. In principle the model should be, as far as possible, a detailed description of what we believe is happening in real biological situation but, in order to keep the model tractable, we are forced to compromise between efficiency and biological representation, i.e. one needs to find whatever is relevant for the description of the phenomenon leaving out the irrelevant details.
Unfortunately there are no rules which allow us to discriminate; the only way to proceed is to refer to biological knowledge and experience. In any case, before using any model for prediction, the model must be validated against past experiments. A validated model, and simulator, can then be used, within certain limits, to simulate and predict new experiments. In what follows we describe these three steps: modeling, validation and simulation.
Designing the model: General framework
In dealing with modeling of the cancer-immune system-vaccine interaction and competition one should be aware that this competition can play a crucial role besides therapeutical actions. This competition may possibly end up either with the elimination of the cancer cells, or the progressive invasion by cancer cells of other tissues or organs.
The goal of medical treatments is to enhance the immune response by activating the immune defense and/or specializing the ability of immune cells to identify the presence of the tumor. Immune competition is a phenomenon which involves aggressive cells or particles (either external non-self pathogens or self-modified or corrupted cells) and the various populations of the immune system.
The immune system appears to be a distributed system which lacks central control, but which, nevertheless, performs its complex task in an extremely effective and efficient way. Complexity, in this framework, is driven by the fact that interactions are developed at different scales (i.e. the cellular dynamics are ruled by sub-cellular interactions) and different mechanisms operate on the same subject (mechanical for the dynamics and biological for the immune competition). The state of the art of the immune mechanisms and its competition with cancer has been described in Sec. 1 and referred literature. Owing to the rapid progress of biological knowledge this is rapidly changing.
A model is a mapping from a real-world domain to a mathematical domain; thus it highlights some of the essential believed properties while ignoring believed unessential ones. A good model must be relevant, capturing the essential properties of the phenomenon; computable, driving computational knowledge into mathematical representation; understandable, offering a conceptual framework for thinking about the scientific domain; and extensible, allowing the inclusion of additional real properties in the same mathematical scheme.
In the framework of immune system competition, relevant means that the model should be able to capture the essential properties of the system, namely its organization and dynamic behavior; computable refers to the model's ability to simulate both the dynamic behavior and the evolution and interactions of system entities; computational possibilities for understanding the immune competition. Understandable means that the model must reproduce concepts and ideas of tumor immunology while opening new computational possibilities for understanding immune competition; finally extensible refers to the possibility to include new immunology concepts and knowledge with limited effort using the same mathematical and computational framework.
The immune system is characterized by great complexity so that it is very difficult, or even impossible, to develop a detailed mathematical description of all phenomena related to the immune competition which satisfies all the above properties. A significant effort has recently been devoted to searching for an appropriate mathematical approach to describe the immune system-tumor competition (see Ref. 2 for a recent review) . However, if one focuses attention on specific types of interactions, one may attempt to develop ad hoc models for a specific phenomenon at the chosen observation and representation scale. Extensive descriptions of subcellular versus larger scales of modeling can be found in Refs. 3, 5 and 17.
SimTriplex model
To satisfy the requirements for conceiving a good model we used an approach which reproduces ab initio the kinetic description of the interactions and diffusion of each relevant biological entity. Our model, hereafter referred as SimTriplex model, describes immune competition using an agent-based method. These methods are now very popular and find applications in various fields. We used a lattice gas automata (LGA) technique which allows us to describe, in a defined space, the immune system entities with their different biological states and the interactions between different entities. We restrict ourselves to a two-dimensional physical space as the organ (the mouse mammary gland) which we need to represent is almost flat. Extension to a three-dimensional physical space is possible, but it would obviously have a higher computational cost. The evolution in space and time of the system is generated from the interactions and diffusion of the different entities.
The major advantage of this technique is that the entities and the relationships can be described in terms that are very similar to the biological world. The intrinsic nonlinearity of the system is treated with no additional effort. The approach is thus biologically understandable and relevance is granted by the included biological details; it is flexible and extensible as the behavior of entities is modelled using up-to-date biological knowledge and can be easily modified to reflect observations from biological experiments; it is computable as it directly reproduces the behavior described by kinetic equations. This class of model can be seen as the computational counterpart of the generalized kinetic model.
Compared to the complexity of the real biological system our model is still very naive and it can be extended in many aspects. However, the model is sufficiently complete to describe the major aspects of the phenomenon and, after tuning the model parameters, it can predict the response to a vaccination schedule that prevented the formation of solid tumors in mice.
Entities and their representation
To describe the cancer-immune system competition one needs to include all the entities (cells, molecules, adjuvants, etc.) which biologists recognize as relevant in the competition. The choice of entities was driven by the experimental data on Triplex vaccine previously described in Sec. 1.
These entities, which are either cells or molecules, have mechanical and biological states: position, lifetime, internal states and specificity. Position and lifetime are common to all of them; internal states apply only to cellular entities, while specificity can be found both in cellular and molecular entities. The model, which has been fully described in Refs. 18 and 21 includes the entities listed and described in Table 2 .
All various classes of immune functional activity, phagocytosis, immune activation, opsonization, infection and cytotoxicity are described using probability functions and translated into computational rules. Transition from normal to tumor cell is a stochastic event. To mimic the above transition, we have introduced new cancer cells in the lattice at every time step. Once inserted in the system, cancer cells duplicate and, very rarely, die by apoptosis. Cancer cell duplication is included as a probabilistic event at each cancer cell, once per cycle. The cancer cell population grows following an exponential law with parameters chosen to fit qualitatively the tumor growth observed in real mice.
Position and lifetime
Position, in our scheme, refers to the lattice-cell in which the entities are located. As interactions between entities can occur only between those entities which are located in the same lattice-cell this is the first parameter which controls entities interactions. We do not consider velocity as this is not relevant for the present state of the model. Changes in position are achieved with diffusion instead of collision. Molecule diffusion on the lattice is performed by appropriate change of the concentrations of entities on the lattice, while cellular entities are allowed to move individually, with uniform probability, between neighboring lattice-cells in the grid.
The tissue is represented as a two-dimensional triangular lattice (six neighbor sites) L × L, with periodic boundary conditions in both directions (up-down, leftright). The lattice is taken to represent here a portion of mammary tissue of the mouse.
Lifetime. Both cellular and molecular entities have age structure. Molecular entities are generated according to specific biological rules, interact and degrade after a finite lifetime. Cellular entities are generated by specialized organs (bone marrows), interact, eventually duplicate and become anergic, and die by apoptosis after a finite lifetime. In the normal state the mean number of cellular entities is given by the leukocyte formula. To mimic this fact, we increase (naive cells generation) or decrease (cell's death by apoptosis) the total number of cells according to mean reversion stochastic model. 26 Death by lysis is considered a state change; it will be described later.
To simulate memory cells, we increase the halflife of TH, TC and B cells after successful interaction with target antigens. To track the age of cellular entities we keep a record of the number of time-steps since cell birth (from stem cells or by clonal division). The death probability reaches the value of 1 when the age reaches twice the half life.
Internal states
Internal states of each cell type are summarized in Table 3 . The biological meaning of internal states are described in detail in Ref. 18 . Each cell can be in a different internal state and all cells are tracked individually throughout the course of an experimental run. Internal state changes of the immune system's cells reflect the biological knowledge of adaptive immunity in the presence of external antigens, so we omit their description here. Mammary carcinoma is a poorly immunogenic tumor, so as we mentioned in Sec. 3.1, it escapes immune system defense. Consequently the interaction of the immune system cells with tumor cells is a low probability event.
Internal state changes are driven by the interactions occurring in the system (see Sec. 5.2.2). In the following we describe only the initial states, which will then determine the system evolution of all entities and the state changes for tumor and vaccine cells.
APC, TH and B cells are initialized as Active; TC cells are initialized as Resting; VC are initialized as PresI while CC are stochastically set as PresI with a high probability. All entities are initialized with their default lifetime (see Age).
All cellular entities will then change their internal status following a successful interaction with another entity (hereafter referred to as positive interaction) or by internal processing. State changes are better described following the state's evolution of each entity since their entry into the lattice (see Sec. 5.2.2). Cancer and Simple molecular entities, like antibodies or Tumor Associated Antigens, are represented using their binding site (receptors) and each of them have predefined lifetimes. Representation of cellular entities include receptors, binding site and lifetime.
The receptor-coreceptor binding among the entities is described in terms of matching between binary strings with fixed directional reading frame. Bit-strings represent the generic "binding site" between cells (through their receptors) and target molecules (through peptides and epitopes). Every cellular entity is represented by a number of molecules, including the receptor. The repertoire is then defined as the cardinality of the set of possible instances of entities which are different for at least one bit, in between the ones included in the binary string which is used to represent their attributes.
Indeed, the cells equipped with binding sites and the antibodies, have a potential repertoire of 2 Nel , where N e indicates the number of binary strings used to represent receptors, MHC-peptide complexes, and epitopes of the entity e. Other entities do not need to be specified by binary strings so their repertoire is represented by a single entity (i.e. N e = 1). Examples include cytokine molecules such as interferon−γ and the danger signal.
14 As receptor entities are represented by bit strings, the only information available is a "similarity" between bit strings. A standard measure of similarity between two bit strings is the so-called Hamming distance which is just the number of mismatching bits.
b The interactions between two entities equipped with receptors are defined by a probability measure m(l), called affinity potential, which is a function of the Hamming distance, m, between the binary strings representing the two entities' binding site. The probability v(m), for two strings s and s having Hamming distance m, is maximum when all corresponding bits are complementary (0 ↔ 1), i.e. when the Hamming distance between s and s is equal to the bit string length, m = l, while it must be 0 when the s and s are equal, i.e. m = 0. However, for our purpose we require that the affinity function drop to zero starting from a threshold value m c of the Hamming distance. This means that binding will only be possible if the two entities do not differ too much, i.e. their Hamming distance is greater than m c . A way to translate these requirements is to define v(l) as:
where υ c ∈ (0, 1) is a free parameter which determines the slope of the function whereas m c (l/2 < m c ≤ l) is the assigned threshold value below which no binding is allowed.
Interactions
In this section we will describe interactions following the evolution of the simulator for the first few steps. First of all we must remember that interactions occur only if two entities stay in the same site. Taking into account that a time step is 8 hours we can say that entities in a site are those entities that a single entity encounters during 8 hours. Time t = 0 corresponds to the atypical hyperplasia, i.e. first appearance of tumor cells. For "early schedule" time t = 0 corresponds also to the first vaccine injection. An interaction between two entities is a complex action which eventually end with a state change of one or both entities. Interactions can be specific or aspecific. Specific interactions need a recognition phase between the two entities (e.g. B ↔ TAA); recognition is based on Hamming distance and affinity function and is eventually enhanced by adjuvants. We refer to positive interaction when this first phase occurs successfully. Aspecific interactions do not have a recognition phase (e.g. DC ↔ TAA). When two entities, which may interact, lie in the same lattice site, then they interact with a probabilistic law. All entities which may interact and are in the same site have a positive interaction. The first positive interaction is between vaccine cells and cytotoxic T cells (TC -VC Interaction). Vaccine cells are engineered in such a way that they are presenting MHC class I (status Presl ) and TC are in the state in which they are released from the thymus (status Active). Then, if the TC (CD8) cell receptor matches with a non-zero affinity with the allogeneic MHCI, the VC dies by lysis and releases TAA. Allogenic-MHC present in the vaccine guarantees a non-zero affinity. Positive interaction produces TC duplication (state change into Duplica) and increases TC lifetime by one time cycle (8 hours). Once TAA are released they can interact with Antigen Presenting Cells (APC), (i.e. Macrophages (MP), Dendritic cells (DC) and B cells) or antibodies. Positive APC↔TAA interaction will have the following effect: (i) TAA is ingested by APC; (ii) APC will change state and become presenting. A presenting APC is able to stimulate other cells (TC, TH). Stimulated TH produce Interleukin-2 (IL-2). A positive interaction TH↔B will change the state of the B cell into Plasma Cell (PLB) and the humoral response begins with antibody production. This briefly describes the major interactions included in 
SimTriplex. They can be divided into standard interaction of the immune system (B ↔ Ag; Ab ↔ Ag; TH ↔ B; TH ↔ MP; MP ↔ IC; MP ↔ Ag; DC ↔ Ag; TH ↔ DC;) and interactions which occurs in presence of tumor and vaccine (TC ↔ CC; Ab ↔ CC; NK ↔ CC; Ab ↔ VC; NK ↔ VC). Permitted interactions are shown in Table 4 .
Biological functions
The model includes the mechanism of haematopoiesis as described in Ref. 21 . The simulator performs the process of thymic selection of T -cells (TH + TC) as described in Ref. 21 . It generates a repertoire of MHC-restricted, self-tolerant T -cells using selective processes that mimic the events taking place in the thymus during T -cell maturation. 1, 16 Selection has two phases: positive and negative (both stochastic). In the positive selection phase the T -cells that have low affinity to the MHC molecules taken alone (class I for TC and class II for TH) are eliminated because they are not useful. In the negative selection phase, the T -cell receptors are confronted with the MHC attached to a self peptide taken from a suitable set of binary strings; in the case of a high match, the T -cell is eliminated to limit autoreactivity.
Biological diversity
Biological diversity between different individuals is a well-established fact in biology. This diversity originates from many parameters, both individual and environmental, and it is, and probably will be in the future, impossible to model it on the basis of biological and environmental parameters. We mimic this diversity in a probabilistic manner. All the events, described above, are driven by probability laws. These laws are computed by a uniform random number generator whose random number sequence is determined by an initial seed. In the simulator described below different individuals are identified by different seeds, so that the sequence of probabilistic events is different in each individual, i.e. each individual has a different sequence of biological events.
Implementing SimTriplex
The high-level architecture of the code can be explained using the following pseudocode.
SimTriplex Simulator
Input: Accept pre-determined inputs (e.g., userspecified vaccine injections, random generation of new B-and T-cells, etc. A setup routine will create the lattice, register the values of the various input parameters and stochastically fill the lattice with all cells populations. Time step interactions will proceed up to a preselected final time.
Tuning and Validating the Model
The model, as sketched in the previous section, has been tuned and validated against existing in vivo experiments. As is known, all models have a certain number of parameters which can be freely chosen in a certain range. Tuning the model refers to the parameter setting on the simulator which we describe briefly below. Most of the parameters were initially chosen in a range suggested on the basis of biological knowledge. We were then forced to choose them in an indirect way, i.e. setting those parameters in such a way that in silico experiments fit in vivo experiments. The data available for model tuning and testing were, for each in vivo tested schedule, the percentage of mice which form solid tumor versus time 1.
The simulator describes the immune response to vaccine for a single mouse up to solid tumor formation, so we need to adjust parameters (mostly probability coefficients) on the simulator such that, for a single mouse, the simulator applied to different vaccine protocols gives the correct results in solid tumor formation delay. We noticed that the simulator's results depend on biological data. As an example, we experienced that for a biologically unrealistic half-life of tumor associated antigens the simulator results did not fit the experimental data. This tuning procedure was done using few, randomly selected, individual mice.
We then turn on the validation phase. Using the parameters found in the above described tuning procedure, we validate the model reconstructing in silico the in vivo experiments. In the following we report our experimental procedure. We performed in silico experiments using the standard good practice statistical procedure: (i) We considered a large population of individual mice. Each individual mouse is characterized by a sequence of uniform numbers which will determine the probabilistic events (5.2.3). (ii) We randomly extract from this population two statistical samples of 100 individual mice (hereafter referred as S 1 and S 2 ) to perform numerical experiments.
The computational time begins when the mouse is six weeks old (the observed time of atypical hyperplasia) and proceeds up to the formation of a solid tumor or up to 400 days. For each protocol we treat all mice in the sample S 2 and we measure the time in which the solid tumor is formed. The percentage of tumor-free mice as a function of age is shown in Fig. 2 for sample S 2 (the same result for sample S 1 has been shown in Ref. 21 ).
We point out here that the restricted number of mice which have been used for the tuning procedure did not belong to any of the two sets used for validation.
The general behavior of the most relevant quantities versus time has already been described in Ref. 21 . Here we show (Fig. 2) 
The Virtual Lab: Computer-Aided Search for a New Schedule
A vaccine schedule is a sequence of vaccine administrations in time. Vaccine schedules are designed empirically, using a combination of immunological knowledge, vaccine wisdom experience, and practical constraints. The issue of the optimal or even simply good schedule is never properly analyzed: the main reason for that is, at preclinical stage, the cost in time and money of the experiments and at clinical stage the risk to patient health. This is particularly true in cancer immunopreventive approaches, like the Triplex vaccine, which must keep a high level of protective immunity against a continuing generation of cancer cells, ideally for the entire lifetime of the host.
In what follows, we describe how we tried to design, at preclinical stage, a new schedule for Triplex vaccine using the in silico lab. First of all one must remember that the simulator can handle only one virtual mouse at a time, and "adjustments" in schedule design can be tried only for that mouse.
Having this in mind, we proceed using as basic vaccination unit a cycle of four injections, each followed by three days of rest. The time, in units of days, at which the first cycle ends is given by C 1 + R 1 where C 1 = 12 is the time of the vaccine administration and R 1 is the rest time after the first cycle. The time at which Early schedule ends (which is composed by three cycles with a constant rest time of fourteen days) is then given by 
2)
The schedule S is then defined by choosing the total number of added cycles, n, and the values of R k . Another vaccine cycle was added, after time interval R k , when the number of cancer cells begins to grow again. We successively tried to minimize n, increasing R k . This procedure was not done automatically and, clearly, does not guarantee that found schedule is optimal. At the end of this procedure, we were able to find a schedule of 44 injections.
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The schedule was then applied to all mice belonging to S 1 , obtaining 85% of solid tumor prevention. In order to search for an optimal, i.e. minimal, vaccination schedule we then attacked the problem using a non standard operation research technique namely Genetic Algorithms (GAs) adaptive heuristic search. 15 We represent a vaccine schedule as a binary vector in which each position is a time step of the simulator. If a vaccine administration is provided at that timestep, the vector element is set to 1, otherwise is 0. The thus constructed binary vector represents a vaccine schedule. The evolutionary algorithm tries to find the best vector which minimizes the objective function.
In setting up the objective function we must take into account two fundamental and competing requirements: (i) any schedule must be an effective one, i.e. the mouse survival time must reach 400 days; (ii) the best schedules must provide mice survival with the minimum number of vaccine injections. Any evolutionary approach which just takes into consideration the first requirement will produce a set of vectors with several ones, thus, not minimal. If instead, we take into consideration just the second requirement, we will have a set of vectors full of zeroes, and thus very likely we will obtain a non effective schedule. Any fitness function therefore must be, at least, a two-variable function of type f (n, s, . . .) where n is the number of injections, and s is the number of timesteps survived by the mouse. Also, f must satisfy the following two properties: We restrict ourselves to the simple case of a two-variable function and we choose the following objective function: f (n, s) = n 2 s (7.5) which satisfies the properties (7.3) and (7.4) . Obviously, the objective function (7.5) has to be minimized. In setting the GA optimal search, 22 we randomly chose 10 virtual mice over the 100 of the sample S 1 . Each run of the GA took about 36 hours on a 686-class PC machine. All the 10 virtual mice gave similar, but obviously not identical, results. They all got complete prevention of mammary carcinoma with 19 vaccine injections, against the 59 required by Chronic vaccination schedule. The GA proposed schedules avoided solid tumor formation, but the cancer cells reached an unsafe level. Indeed, we tried the suggested GA schedules against the entire sample of mice. In all cases only ∼ 20% of mice were tumor free. From this experience we concluded that:
• a genetic search should be constrained on a biological basis. As high level of cancer cells may be unsafe for a real host, one must use a constrained optimal search.
• The designed vaccination schedule must not only cover a single individual, but also provide good protection for a large class of individuals. So, the search should take into account different individuals simultaneously.
Having this in mind, we set up a constrained genetic search using a three-variable objective function, namely:
where β is defined as:
o t h e r w i s e , (7.7) and N chosen equal to 150 timesteps in order to distinguish the transient phase from the steady one. Equation (7.6) does take into account only a single mouse. As we noticed before, this is still unsatisfactory as the schedule predicted may not be effective for a high percentage of the sample. To overcome this problem, we apply the same strategy to 8 randomly chosen mice simultaneously. 13 This GA search was able to find a 35 injection schedule which was effective on ∼ 85% of the sample S 1 .
All in vivo and in silico schedules are summarized in Fig. 3 . This figure clearly shows that vaccine modeling can be effective in finding better schedules. 
Conclusions
We have described a successful new way to prevent tumors through the stimulation of the immune system and a computational model that faithfully reproduces the biological results. The combination of the lattice gas model with a genetic algorithm provides a novel way to predict effective vaccination schedules with a reduced number of vaccine administrations.
We are currently implementing in vivo the in silico predictions of the model in order to verify its plausibility. This is a conclusion rarely seen in the collaboration between life scientists and modelers, because the former frequently provide useful input data, but very rarely put to work the output.
